June 12 (Reuters) - The U.S. Food and Drug Administration said on Friday it has ‌expanded the use of Dexcom's Stelo ‌Glucose Biosensor System to children with diabetes, making it the ​first over-the-counter continuous glucose monitor for pediatric use.

• The device is cleared for patients aged two years and older who do not use ‌insulin. The FDA ⁠had previously cleared Stelo for adults aged 18 and older in March ⁠2024.

• Stelo uses a wearable sensor and smartphone app to track glucose levels, showing readings and ​trends every ​15 minutes. Each ​sensor can last up ‌to 15 days, though wear time may be shorter in children, the FDA said.

• The device can help children and caregivers understand how meals, exercise and lifestyle changes affect glucose levels, ‌the agency said.

• The ​FDA said children should use ​the device ​under adult supervision, and users should ‌consult a healthcare provider before ​changing medication ​based on its readings.

• The device is not meant for people with problematic low ​blood sugar, ‌as it is not designed to alert ​users about that potentially dangerous condition.

(Reporting by ​Kunal Das in Bengaluru)